CO4920244A1 - Compuestos heterociclicos, composiciones farmaceuticas que los comprenden, y metodos para inhibir la liberacion del peptido beta-amiloide y/o sus sintesis mediante el uso de dichos compuestos - Google Patents
Compuestos heterociclicos, composiciones farmaceuticas que los comprenden, y metodos para inhibir la liberacion del peptido beta-amiloide y/o sus sintesis mediante el uso de dichos compuestosInfo
- Publication number
- CO4920244A1 CO4920244A1 CO98010854A CO98010854A CO4920244A1 CO 4920244 A1 CO4920244 A1 CO 4920244A1 CO 98010854 A CO98010854 A CO 98010854A CO 98010854 A CO98010854 A CO 98010854A CO 4920244 A1 CO4920244 A1 CO 4920244A1
- Authority
- CO
- Colombia
- Prior art keywords
- substituted
- diand
- monoand
- heterocyclic
- amino
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
- C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D257/04—Five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D233/28—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D263/16—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/08—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D277/10—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/08—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D277/12—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Hospice & Palliative Care (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Abstract
noAND#8209; y diAND#8209;heteroarilamino, monoAND#8209; y diAND#8209;heterocíclico amino, y aminas aUn método para inhibir la liberación de péptidos ß-amiloidesy/o su síntesis en una célula, cuyo métosimétricas diAND#8209;sustituidas que tienen diferdo comprende administrar a dicha célula una cantidentes sustituyentes seleccionados de alquil, alquiad de un compuesto o una mezcla de compuestos que l substituido, aril, heteroaril y heterocíclico, cicloalquilo, arilo, heteroarilo, y heterocíclico; es eficaz para inhibir la liberación celular y/o la síntesis de péptidos ß-amiloides donde dichos coy (iii)donde A, conjuntamente con AND#8209;C=NAND#mpuestos están representados por la fórmula I: A-B8209;, forman un grupo heterocíclico que está opcionalmente fusionado para formar un sistema de anil-C donde A está seleccionado del grupo que consiste en: donde R1 está seleccionado del grupo que conlo biAND#8209; o multiAND#8209;fusionado (que prefsiste en alquilo, alquenilo, alquinilo, cicloalquieriblemente no tiene más de cinco anillos fusionados) con una o más estructuras de anillos seleccionlo, cicloalquenilo, alquilo substituido que tiene ados del grupo que consiste en cicloalquilo, ciclode 1 a 3 sustituyentes seleccionados del grupo que consiste en alcoxi, alcoxi substituido; acilo, acalquenilo, heterocíclico, heteroarilo, el cual, a su vez, en cada una de dichas estructuras de anillilamino, amino, aminoacilo, ésteres aminocarboxi, ciano, cicloalquilo, halógeno, hidróxilo, carboxilo está opcionalmente sustituida con 1 a 4 sustituyentes seleccionados del grupo que consiste en hidro, carboxialquilo, oxiacilo, oxiacilamino, tiol, toxilo, halo, alcoxi, alquilAND#8209;OAND#8209;subsioalcoxi, tioalcoxi substituido, arilo, heteroariltituido, en donde el alquilo substituido tiene de o, heterocíclico, ariloxi, tioariloxi, heteroariloxi, tioheteroariloxi, nitro, y mono- y di-alquilam1 a 3 sustituyentes seleccionados del grupo que coino, mono- y di-(alquilo substituido)amino, mono- nsiste en alcoxi, alcoxi substituido, acilo, acilamino, amino, aminoacilo, ésteres aminocarboxi, ciay di- arilamino, mono- y di-heteroarilamino, mono- y di-heterocíclico amino, y aminas asimétricas dino, cicloalquilo, halógeno, hidróxilo, carboxilo, - sustituidas que tienen diferentes sustituyentes carboxialquilo, oxiacilo, oxiacilamino, tiol, tioaseleccionados de alquil, alquil substituido, aril,lcoxi, tioalcoxi substituido, arilo, heteroarilo, heteroaril y heterocíclico, alquenilo substituidoheterocíclico, ariloxi, tioariloxi, heteroariloxi, tioheteroariloxi, nitro, y monoAND#8209; y diAND# que tiene de 1 a 3 sustituyentes seleccionados de8209;alquilamino, monoAND#8209; y diAND#8209;(alqul grupo que consiste en alcoxi, alcoxi substituidoilo substituido)amino, monoAND#8209; y diAND#8209;, acilo, acilamino, amino, aminoacilo, ésteres aminocarboxi, ciano, halógeno, hidróxilo, carboxilo, arilamino, monoAND#8209; y diAND#8209;heteroarilamino, monoAND#8209; y diAND#8209;heterocíclico amincarboxialquilo, cicloalquilo, oxiacilo, oxiacilamino, tiol, tioalcoxi, tioalcoxi substituido, arilo,o, y aminas asimétricas diAND#8209;sustituidas que tienen diferentes sustituyentes seleccionados de heteroarilo, heterocíclico, nitro, y mono- y di-alquilamino, mono- y di- (alquilo substituido)aminoalquil, alquil substituido, aril, heteroaril y het, mono- y di-arilamino, mono- y di-heteroarilaminoerocíclico, tioalcoxi, alquilAND#8209;SAND#8209;substituído, en donde el alquilo substituido tiene d, mono- y di-heterocíclico amino, y aminas asimétricas di-sustituidas que tienen diferentes sustituye 1 a 3 sustituyentes seleccionados del grupo que consiste en alcoxi, alcoxi substituido, acilo,- 12entes seleccionados de alquil, - 2 -alquil substituido, aril, heteroaril y heterocíclico, alquinilo -acilamino, amino, aminoacilo, ésteres aminocarbosubstituido que tiene de 1 a 3 sustituyentes selecxi, ciano, cicloalquilo, halógeno, hidróxilo, carbcionados del grupo que consiste en alcoxi, alcoxi oxilo, carboxialquilo, oxiacilo, oxiacilamino, tiol, tioalcoxi, tioalcoxi substituido, arilo, heterosubstituido, acilo, acilamino, amino, aminoacilo, arilo, heterocíclico, ariloxi, tioariloxi, heteroaésteres aminocarboxi, ciano, halógeno, hidróxilo, riloxi, tioheteroariloxi, nitro, y monoAND#8209; ycarboxilo, carboxialquilo, cicloalquilo, oxiacilo, oxiacilamino, tiol, tioalcoxi, tioalcoxi substitu diAND#8209;alquilamino, monoAND#8209; y diAND#820ido, arilo, heteroarilo, heterocíclico, nitro, y m9;(alquilo substituido)amino, monoAND#8209; y diAND#8209;arilamino, monoAND#8209; y diAND#8209;heterono- y di-alquilamino, mono- y di-(alquilo substitoarilamino, monoAND#8209; y diAND#8209;heterocícliuido)amino, mono- y di-arilamino, mono- y di-heterco amino, y aminas asimétricas diAND#8209;sustituioarilamino, mono- y di-heterocíclico amino, y aminas asimétricas di-sustituidas que tienen diferentedas que tienen diferentes sustituyentes seleccionados de alquil, alquil substituido, aril, heteroaris sustituyentes seleccionados de alquil, alquil sul y heterocíclico, nitro, ciano, carboxilo, ésterebstituido, aril, heteroaril y heterocíclico, cicloalquilo substituido que tiene de 1 a 5 (preferibles carboxílicos, alquilo, alquilo substituido que tmente de 1 a 3) sustituyentes seleccionados del griene de 1 a 3 sustituyentes seleccionados del grupo que consiste en alcoxi, alcoxi substituido, acilupo que consiste en hidroxi, acilo, aciloxi, alquio, acilamino, amino, aminoacilo, ésteres aminocarbl, alquil substituido, alcoxi, alcoxi substituido, alquenilo, alquenilo substituido, alquinil, alquioxi, ciano, cicloalquilo, halógeno, hidróxilo, carnil substituido, amino, aminoacilo, alcarilo, arilboxilo, carboxialquilo, oxiacilo, oxiacilamino, tio, ariloxi, carboxilo, carboxialquilo, ciano, halool, tioalcoxi, tioalcoxi substituido, arilo, heter, nitro, heteroarilo, tioalcoxi, tioalcoxi substitoarilo, heterocíclico, ariloxi, tioariloxi, heterouido y trihalometilo, cicloalquenilo substituido qariloxi, tioheteroariloxi, nitro, y monoAND#8209; y diAND#8209;alquilamino, monoAND#8209; y diAND#82ue tiene de 1 a 5 sustituyentes seleccionados del 09;(alquilo substituido)amino, monoAND#8209; y diAgrupo que consiste en hidroxi, acilo, aciloxi, alqND#8209;arilamino, monoAND#8209; y diAND#8209;heteuil, alquil substituido, alcoxi, alcoxi substituidroarilamino, monoAND#8209; y diAND#8209;heterocíclo, alquenilo, alquenilo substituido, alquinil, alqico amino, y aminas asimétricas diAND#8209;sustituuinil substituido, amino, aminoacilo, alcarilo, aridas que tienen diferentes sustituyentes seleccionilo, ariloxi, carboxilo, carboxialquilo, ciano, haados de alquil, alquil substituido, aril, heteroarlo, nitro, heteroarilo, tioalcoxi, tioalcoxi substil y heterocíclico, alquenilo, alquenilo substituiituido y trihalometilo; arilo, heteroarilo y heterocíclico; Z está seleccionado del grupo que consisdo que tiene de 1 a 3 sustituyentes seleccionados del grupo que consiste en alcoxi, alcoxi substituite en (a) un grupo que tiene la fórmula -CX´X"C(O)- donde X´ es hidrógeno, hidroxi o flúor; X" es hido, acilo, acilamino, amino, aminoacilo, ésteres adrógeno, hidroxi o flúor, o X´ y X" conjuntamente minocarboxi, ciano, halógeno, hidróxilo, carboxilo, carboxialquilo, cicloalquilo, oxiacilo, oxiacilaforman un grupo oxo; (b) un grupo que tiene la fórmino, tiol, tioalcoxi tioalcoxi substituido, arilomula AND#8209;TAND#8209;C´X´X"C(O)AND#8209; donde , heteroarilo, heterocíclico, nitro, y monoAND#820T está seleccionado del grupo que consiste en oxíg9; y diAND#8209;alquilamino, monoAND#8209; y diANDeno, azufre, y AND#8209;NR3 donde R3 es hidrógeno,#8209; (alquilo substituido)amino, monoAND#8209; y acilo, alquilo, arilo o heteroarilo; X´ es hidróg diAND#8209;arilamino, monoAND#8209; y diAND#8209;eno o flúor, X" es hidrógeno, hidroxi o flúor, o Xheteroarilamino, monoAND#8209; y diAND#8209;hetero´ y X" conjuntamente forman un grupo oxo; y (c) un grupo que tiene la fórmula AND#8209;C´X´X" AND#82cíclico amino, y aminas asimétricas diAND#8209;sustituidas que tienen diferentes sustituyentes selec09;TAND#8209;C(O)AND#8209; donde T está seleccionacionados de alquil, alquil substituido, aril, hetedo del grupo que consiste en oxígeno, azufre, y ANroaril y heterocíclico,alquinilo, alquinilo substiD#8209;NR3 donde R3 es hidrógeno, un grupo acilo, tuido que tiene de 1 a 3 sustituyentes seleccionadalquilo, arilo o heteroarilo; X´ es hidrógeno o flos del grupo que consiste en alcoxi, alcoxi substiúor, X" es hidrógeno, hidroxi o flúor, o X´ y X" conjuntamente forman un grupo oxo; R2 está selecciotuido, acilo, acilamino, amino, aminoacilo, ésteres aminocarboxi, ciano, halógeno, hidróxilo, carboxnado del grupo que consiste en alquilo, alquilo suilo, carboxialquilo, cicloalquilo, oxiacilo, oxiacbstituido que tiene de 1 a 3 sustituyentes seleccionados del grupo que consiste en alcoxi, alcoxi suilamino, tiol, tioalcoxi, tioalcoxi substituido, arilo, heteroarilo, heterocíclico, nitro, y monoANDbstituido, acilo, acilamino, amino, aminoacilo, és#8209; y diAND#8209;alquilamino, monoAND#8209; y dteres aminocarboxi, ciano, cicloalquilo, halógeno, hidróxilo, carboxilo, carboxialquilo, oxiacilo, oiAND#8209; (alquilo substituido)amino, monoAND#8209; y diAND#8209;arilamino, monoAND#8209; y diAND#8xiacilamino, tiol, tioalcoxi, tioalcoxi substituid209;heteroarilamino, monoAND#8209; y diAND#8209;heo, arilo, heteroarilo, heterocíclico, ariloxi, tioariloxi, heteroariloxi, tioheteroariloxi, nitro, yterocíclico amino, y aminas asimétricas diAND#8209;sustituidas que tienen diferentes sustituyentes s monoAND#8209; y diAND#8209;alquilamino, monoAND#8eleccionados de alquil, alquil substituido, aril, 209; y diAND#8209;(alquilo substituido)amino, monoheteroaril y heterocíclico, arilo, heteroarilo, heAND#8209; y diAND#8209;arilamino, monoAND#8209; y diAND#8209;heteroarilamino, monoAND#8209; y diAND#terocíclico, AND#8209;NHC(O)R10 , AND#8209;NHSO2 R10 , AND#8209;C(O)NH2 , AND#8209;C(O)NHR10 , AND#8
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US80826397A | 1997-02-28 | 1997-02-28 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO4920244A1 true CO4920244A1 (es) | 2000-05-29 |
Family
ID=25198310
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CO98010854A CO4920244A1 (es) | 1997-02-28 | 1998-02-27 | Compuestos heterociclicos, composiciones farmaceuticas que los comprenden, y metodos para inhibir la liberacion del peptido beta-amiloide y/o sus sintesis mediante el uso de dichos compuestos |
Country Status (22)
| Country | Link |
|---|---|
| EP (1) | EP0968198A1 (es) |
| JP (1) | JP2001513107A (es) |
| KR (1) | KR20000075767A (es) |
| CN (1) | CN1253554A (es) |
| AR (1) | AR011164A1 (es) |
| AU (1) | AU6662298A (es) |
| BR (1) | BR9807876A (es) |
| CA (1) | CA2278674A1 (es) |
| CO (1) | CO4920244A1 (es) |
| EA (1) | EA199900778A1 (es) |
| HR (1) | HRP980093A2 (es) |
| HU (1) | HUP0001293A3 (es) |
| ID (1) | ID22873A (es) |
| IL (1) | IL130851A0 (es) |
| NO (1) | NO994016L (es) |
| NZ (1) | NZ336613A (es) |
| PE (1) | PE59399A1 (es) |
| PL (1) | PL335424A1 (es) |
| TR (1) | TR199902071T2 (es) |
| WO (1) | WO1998038177A1 (es) |
| YU (1) | YU7998A (es) |
| ZA (1) | ZA981627B (es) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6635632B1 (en) | 1996-12-23 | 2003-10-21 | Athena Neurosciences, Inc. | Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds |
| BR9812773A (pt) * | 1997-12-22 | 2000-10-10 | Elan Pharm Inc | "alfa-amino-epsilon-caprolactamas policìclicas e compostos relacionados" |
| US6552013B1 (en) | 1998-06-22 | 2003-04-22 | Elan Pharmaceuticals, Inc. | Deoxyamino acid compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds |
| US6569851B1 (en) | 1998-06-22 | 2003-05-27 | Elan Pharmaceutials, Inc. | Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds |
| WO1999067219A1 (en) * | 1998-06-22 | 1999-12-29 | Elan Pharmaceuticals, Inc. | Compounds for inhibiting beta-amyloid peptide release and/or its synthesis |
| US6509331B1 (en) | 1998-06-22 | 2003-01-21 | Elan Pharmaceuticals, Inc. | Deoxyamino acid compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds |
| US6774125B2 (en) | 1998-06-22 | 2004-08-10 | Elan Pharmaceuticals, Inc. | Deoxyamino acid compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds |
| US6528505B1 (en) | 1998-06-22 | 2003-03-04 | Elan Pharmaceuticals, Inc. | Cyclic amino acid compounds pharmaceutical compositions comprising same and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds |
| US6737038B1 (en) | 1998-11-12 | 2004-05-18 | Bristol-Myers Squibb Company | Use of small molecule radioligands to discover inhibitors of amyloid-beta peptide production and for diagnostic imaging |
| CA2360740A1 (en) | 1999-03-02 | 2000-09-08 | Boehringer Ingelheim Pharmaceuticals, Inc. | Compounds useful as reversible inhibitors of cathepsin s |
| US7160880B1 (en) | 1999-05-14 | 2007-01-09 | Cenes Limited | Short-acting benzodiazepines |
| GB9911803D0 (en) * | 1999-05-20 | 1999-07-21 | Merck Sharp & Dohme | Therapeutic combination |
| WO2001010846A2 (en) * | 1999-08-05 | 2001-02-15 | Igt Pharma Inc. | 1,4-diazepine derivatives for the treatment of diseases related to the central nervous system |
| US6420364B1 (en) | 1999-09-13 | 2002-07-16 | Boehringer Ingelheim Pharmaceuticals, Inc. | Compound useful as reversible inhibitors of cysteine proteases |
| AU2001261728A1 (en) | 2000-05-17 | 2001-11-26 | Bristol-Myers Squibb Pharma Company | Use of small molecule radioligands for diagnostic imaging |
| AU783857B2 (en) | 2000-06-01 | 2005-12-15 | Bristol-Myers Squibb Pharma Company | Lactams substituted by cyclic succinates as inhibitors of a beta protein production |
| DE10029077A1 (de) * | 2000-06-13 | 2001-12-20 | Bayer Ag | Thiazolylsubstituierte Heterocyclen |
| US6432944B1 (en) | 2000-07-06 | 2002-08-13 | Bristol-Myers Squibb Company | Benzodiazepinone β-amyloid inhibitors: arylacetamidoalanyl derivatives |
| AR039059A1 (es) * | 2001-08-06 | 2005-02-09 | Sanofi Aventis | Compuesto derivado de acilaminotiazol, su utilizacion, procedimientos para prepararlo, composicion farmaceutica que lo comprende, y compuestos intermediarios |
| FR2840899B1 (fr) * | 2002-06-12 | 2005-02-25 | Sanofi Synthelabo | Derives d'acylaminothiazole, leur preparation et leur utilisation en therapeutique |
| CA2486350A1 (en) | 2002-06-05 | 2003-12-24 | Kaneka Corporation | Process for producing optically active .alpha.-methylcysteine derivative |
| EP1802303B1 (en) | 2004-09-17 | 2011-11-02 | Whitehead Institute For Biomedical Research | Compounds, compositions and methods of inhibiting a-synuclein toxicity |
| US7449486B2 (en) | 2004-10-19 | 2008-11-11 | Array Biopharma Inc. | Mitotic kinesin inhibitors and methods of use thereof |
| UA95907C2 (en) | 2005-05-02 | 2011-09-26 | Эррей Биофарма Инк. | Mitotic kinesin inhibitors and methods of use thereof |
| EP1757290A1 (en) | 2005-08-16 | 2007-02-28 | Zentaris GmbH | Novel triazole derivatives as ghrelin analogue ligands of growth hormone secretagogue receptors |
| EP2081918A2 (en) | 2006-10-03 | 2009-07-29 | Array Biopharma, Inc. | Mitotic kinesin inhibitors and methods of use thereof |
| EP2303847B1 (de) * | 2008-07-16 | 2018-09-05 | Bitop AG | Synthese von zyklischen amidinen |
| WO2011133920A1 (en) | 2010-04-23 | 2011-10-27 | Cytokinetics, Inc. | Certain amino-pyridines and amino-triazines, compositions thereof, and methods for their use |
| AR081331A1 (es) | 2010-04-23 | 2012-08-08 | Cytokinetics Inc | Amino- pirimidinas composiciones de las mismas y metodos para el uso de los mismos |
| AR081626A1 (es) | 2010-04-23 | 2012-10-10 | Cytokinetics Inc | Compuestos amino-piridazinicos, composiciones farmaceuticas que los contienen y uso de los mismos para tratar trastornos musculares cardiacos y esqueleticos |
| EP2431035A1 (en) | 2010-09-16 | 2012-03-21 | Æterna Zentaris GmbH | Novel Triazole Derivatives with Improved Receptor Activity and Bioavailability Properties as Ghrelin Antagonists of Growth Hormone Secretagogue Receptors |
| US8759380B2 (en) | 2011-04-22 | 2014-06-24 | Cytokinetics, Inc. | Certain heterocycles, compositions thereof, and methods for their use |
| US8809372B2 (en) | 2011-09-30 | 2014-08-19 | Asana Biosciences, Llc | Pyridine derivatives |
| CN103435549A (zh) * | 2013-08-14 | 2013-12-11 | 无锡惠飞生物医药技术有限公司 | 5-甲基-7-氨基-5H,7H-二苯并[b,d]氮杂环庚-6-酮的制备方法 |
| CN105646208B (zh) * | 2016-02-24 | 2018-10-16 | 潍坊晶润化工股份有限公司 | 丙酮酸甲酯的制备方法 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2221684A1 (en) * | 1995-06-06 | 1996-12-12 | Athena Neurosciences, Inc. | Novel cathepsin and methods and compositions for inhibition thereof |
-
1998
- 1998-02-24 AR ARP980100812A patent/AR011164A1/es unknown
- 1998-02-24 HR HR08/808,236A patent/HRP980093A2/hr not_active Application Discontinuation
- 1998-02-26 ZA ZA9801627A patent/ZA981627B/xx unknown
- 1998-02-27 CA CA002278674A patent/CA2278674A1/en not_active Abandoned
- 1998-02-27 ID IDW990811A patent/ID22873A/id unknown
- 1998-02-27 YU YU7998A patent/YU7998A/sh unknown
- 1998-02-27 HU HU0001293A patent/HUP0001293A3/hu unknown
- 1998-02-27 EA EA199900778A patent/EA199900778A1/ru unknown
- 1998-02-27 EP EP98908637A patent/EP0968198A1/en not_active Withdrawn
- 1998-02-27 BR BR9807876-3A patent/BR9807876A/pt not_active IP Right Cessation
- 1998-02-27 JP JP53773298A patent/JP2001513107A/ja active Pending
- 1998-02-27 TR TR1999/02071T patent/TR199902071T2/xx unknown
- 1998-02-27 IL IL13085198A patent/IL130851A0/xx unknown
- 1998-02-27 CN CN98802875A patent/CN1253554A/zh active Pending
- 1998-02-27 AU AU66622/98A patent/AU6662298A/en not_active Abandoned
- 1998-02-27 WO PCT/US1998/003373 patent/WO1998038177A1/en not_active Application Discontinuation
- 1998-02-27 CO CO98010854A patent/CO4920244A1/es unknown
- 1998-02-27 PL PL98335424A patent/PL335424A1/xx unknown
- 1998-02-27 KR KR1019997007839A patent/KR20000075767A/ko not_active Application Discontinuation
- 1998-02-27 NZ NZ336613A patent/NZ336613A/en unknown
- 1998-02-27 PE PE1998000144A patent/PE59399A1/es not_active Application Discontinuation
-
1999
- 1999-08-19 NO NO994016A patent/NO994016L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| ZA981627B (en) | 1999-10-05 |
| KR20000075767A (ko) | 2000-12-26 |
| WO1998038177A1 (en) | 1998-09-03 |
| CN1253554A (zh) | 2000-05-17 |
| EP0968198A1 (en) | 2000-01-05 |
| HRP980093A2 (en) | 1998-12-31 |
| CA2278674A1 (en) | 1998-09-03 |
| HUP0001293A1 (hu) | 2000-08-28 |
| PE59399A1 (es) | 1999-06-21 |
| BR9807876A (pt) | 2000-02-29 |
| ID22873A (id) | 1999-12-16 |
| AU6662298A (en) | 1998-09-18 |
| TR199902071T2 (xx) | 2000-01-21 |
| IL130851A0 (en) | 2001-01-28 |
| EA199900778A1 (ru) | 2000-04-24 |
| PL335424A1 (en) | 2000-04-25 |
| NO994016L (no) | 1999-10-18 |
| NO994016D0 (no) | 1999-08-19 |
| YU7998A (sh) | 2002-06-19 |
| NZ336613A (en) | 2001-10-26 |
| JP2001513107A (ja) | 2001-08-28 |
| AR011164A1 (es) | 2000-08-02 |
| HUP0001293A3 (en) | 2000-09-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO4920244A1 (es) | Compuestos heterociclicos, composiciones farmaceuticas que los comprenden, y metodos para inhibir la liberacion del peptido beta-amiloide y/o sus sintesis mediante el uso de dichos compuestos | |
| CO4930282A1 (es) | Cicloalquilo lactama lactona y compuestos relacionados composiciones farmaceuticas que comprenden los mismos metodos para inhibir la liberacion del peptido -amiloide y/o su sintesis mediante el uso de dichos compuestos | |
| ATE36152T1 (de) | Azaprostacycline, verfahren zu ihrer herstellung und ihre pharmazeutische verwendung. | |
| ATE410162T1 (de) | Verfahren zur herstellung einer fein selbstemulgierbaren pharmazeutischen zusammensetzung | |
| MX9206939A (es) | Derivados de piperazina, procedimiento para su preparacion y composicion farmaceutica que los comprende | |
| ES2095942T3 (es) | Derivados de bencenoacetamida inhibidores del vih. | |
| DE69202876T2 (de) | Inhibitoren von N-Myristoyltransferase, deren Verfahren zur Herstellung und die sie enthaltenden pharmazeutischen Zusammensetzungen. | |
| ES2040206T3 (es) | Procedimiento para preparar nuevos compuestos de tiazol. | |
| ATE73790T1 (de) | Amino 5,6,7,8tetrahydronaphtho(2,3b>furanderivate, verfahren zu ihrer herstellung und diese enthaltende arzneimittel. | |
| PT83535B (pt) | Processo para a preparacao de composicoes farmaceuticas contendo derivados de aminoacidos | |
| KR840002404A (ko) | 세포 디짐의 결정성 염의 제조방법 | |
| ATE94409T1 (de) | Verfahren zur behandlung der cardialen sowie der vasculaeren hypertrophie und hyperplasie. | |
| DE3577093D1 (de) | Beta-lactamantibiotika, verfahren zu deren herstellung sowie ihre verwendung als arzneimittel oder wachstumsfoerderer in der tieraufzucht oder als antioxidantien. | |
| ATE75470T1 (de) | Tricyclische 5,6,7,8-tetrahydro-naphtho (2,3b>2,3-dihydrofuran- und 6,7,8,9-tetrahydro-5hbenzocyclohepta (2,3b>-2,3dihydrofuranaminderivate, verfahren zu ihrer herstellung und diese enthaltende arzneimittel. | |
| ES544417A0 (es) | Procedimiento para preparar 8-alquiltio-2-piperazino-pirimido(5,4-d)pirimidinas. | |
| ES2190533T3 (es) | Derivados de tropano utilizables en particular para la deteccion in vivo de transportadores de dopamina. | |
| DE3870167D1 (de) | N-(vinblastinoyl-23)-derivate von 1-aminomethylposphonsaeure, verfahren zu ihrer herstellung und sie enthaltende arzneimittel. | |
| DK1257552T3 (da) | Xanthinderivater, mellemprodukter og anvendelse til behandling af osteoporose | |
| ES2155546T3 (es) | Bencenosulfonil-ureas y -tioureas sustituidas, procedimiento para su preparacion y el uso de preparaciones farmaceuticas basadas en estos compuestos, asi como medicamentos que los contienen. | |
| DK302679A (da) | Hidtil ukendte 2-phenylamino-imidazolin-(2)-er, disses syreadditionssalte laegemidler der indeholder disse samt fremgangsmaader til fremstilling deraf | |
| AR012249A1 (es) | Compuestos de amonio cuaternario, procedimiento para su preparacion, composicion farmaceutica que los contiene, y su uso para la preparacion de medicamentos | |
| DE3880861D1 (de) | 1-dethia-2-thia-cephalosporansaeurederivate, verfahren zur herstellung, ihre verwendung als arzneimittel und sie enthaltende pharmazeutische zusammensetzungen. | |
| DE3764918D1 (de) | 2,6-piperazin-dion-derivate, ihre verfahren zur herstellung und sie enthaltende pharmazeutische zusammensetzungen. | |
| GB1248727A (en) | Benzodiazepine derivatives | |
| DE3373302D1 (en) | Derivatives of aminopyridinecarboxylic acids, methods for their preparation and pharmaceutical compositions containing them |